Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25444545 | 1.00 | HPGD (0.42) | HPGDRAB9ACYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL25444132 | 1.00 | HPGD (0.42) | HPGDRAB9ACYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL23081197 | 1.00 | HPGD (0.42) | HPGDRAB9ACYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL25705661 | 0.86 | HPGD (0.40) | HPGDRAB9ACYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL5907681 | 0.86 | HPGD (0.53) | HPGDRAB9ACYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL2447418 | 0.84 | HPGD (0.40) | HPGDRAB9ACYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL2453016 | 0.84 | HPGD (0.43) | HPGDRAB9ACYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL23081207 | 0.84 | HPGD (0.42) | HPGDRAB9ACYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL25444139 | 0.83 | MTNR1A (0.42) | HPGDRAB9ACYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL23081199 | 0.83 | MTNR1A (0.42) | HPGDRAB9ACYP3A4CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | HPGD 2196/4885RAB9A 2457/4885CYP3A4 1662/4885 |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | HPGD 2196/4885RAB9A 2457/4885CYP3A4 1662/4885 |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | CDK6, CDK3, CDK9 | HPGD 2196/4885RAB9A 2457/4885CYP3A4 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.